BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35218306)

  • 21. [Cutaneous angiosarcoma clinically presenting as Quincke's edema].
    Albrecht M; Hadaschik E; Zimmer L; Livingstone E; Hamacher R; Bauer S; Schadendorf D; Ugurel S
    Hautarzt; 2021 Sep; 72(9):801-804. PubMed ID: 33439269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current and Future Directions for Angiosarcoma Therapy.
    Florou V; Wilky BA
    Curr Treat Options Oncol; 2018 Mar; 19(3):14. PubMed ID: 29520447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study.
    Conic RRZ; Damiani G; Frigerio A; Tsai S; Bragazzi NL; Chu TW; Mesinkovska NA; Koyfman SA; Joshi NP; Budd GT; Vidimos A; Gastman BR
    J Am Acad Dermatol; 2020 Sep; 83(3):809-816. PubMed ID: 31310841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma.
    Samimi M
    Am J Clin Dermatol; 2019 Jun; 20(3):391-407. PubMed ID: 30784027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical and Fluorescence In Situ Hybridization Analysis of MYC in a Series of 17 Cutaneous Angiosarcomas: A Single-Center Study.
    Requena C; Rubio L; Lavernia J; Machado I; Llombart B; Sanmartín O; Traves V; Guillén C; Cruz J
    Am J Dermatopathol; 2018 May; 40(5):349-354. PubMed ID: 29135507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
    Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
    JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018).
    Damato A; Iachetta F; Antonuzzo L; Nasti G; Bergamo F; Bordonaro R; Maiello E; Zaniboni A; Tonini G; Romagnani A; Berselli A; Normanno N; Pinto C
    BMC Cancer; 2020 Aug; 20(1):822. PubMed ID: 32867715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular profiling of an osseous metastasis in glioblastoma during checkpoint inhibition: potential mechanisms of immune escape.
    Mohme M; Maire CL; Schliffke S; Joosse SA; Alawi M; Matschke J; Schüller U; Dierlamm J; Martens T; Pantel K; Riethdorf S; Lamszus K; Westphal M
    Acta Neuropathol Commun; 2020 Mar; 8(1):28. PubMed ID: 32151286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway.
    Murali R; Chandramohan R; Möller I; Scholz SL; Berger M; Huberman K; Viale A; Pirun M; Socci ND; Bouvier N; Bauer S; Artl M; Schilling B; Schimming T; Sucker A; Schwindenhammer B; Grabellus F; Speicher MR; Schaller J; Hillen U; Schadendorf D; Mentzel T; Cheng DT; Wiesner T; Griewank KG
    Oncotarget; 2015 Nov; 6(34):36041-52. PubMed ID: 26440310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy for metastatic renal cell carcinoma.
    Unverzagt S; Moldenhauer I; Nothacker M; Roßmeißl D; Hadjinicolaou AV; Peinemann F; Greco F; Seliger B
    Cochrane Database Syst Rev; 2017 May; 5(5):CD011673. PubMed ID: 28504837
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
    Saito R; Sawada Y; Nakamura M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cutaneous angiosarcoma].
    Fink-Puches R; Smolle J; Beham A; Kerl H; Soyer HP
    Hautarzt; 2000 Jul; 51(7):479-85. PubMed ID: 10969401
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiosarcoma and atypical vascular lesions of the breast: diagnostic and prognostic role of MYC gene amplification and protein expression.
    Fraga-Guedes C; André S; Mastropasqua MG; Botteri E; Toesca A; Rocha RM; Peradze N; Rotmensz N; Viale G; Veronesi P; Gobbi H
    Breast Cancer Res Treat; 2015 May; 151(1):131-40. PubMed ID: 25893585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of a combination of paclitaxel and radiation therapy against cutaneous angiosarcoma: A single-institution retrospective study of 21 cases.
    Seo T; Kitamura S; Yanagi T; Ujiie H
    J Dermatol; 2022 Mar; 49(3):383-386. PubMed ID: 34881462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nation-wide survey of advanced non-melanoma skin cancers treated at dermatology departments in Japan.
    Fujisawa Y; Funakoshi T; Nakamura Y; Ishii M; Asai J; Shimauchi T; Fujii K; Fujimoto M; Katoh N; Ihn H
    J Dermatol Sci; 2018 Dec; 92(3):230-236. PubMed ID: 30527378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
    Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
    Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of angiosarcoma.
    Budd GT
    Curr Oncol Rep; 2002 Nov; 4(6):515-9. PubMed ID: 12354365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches.
    Weiner DM; Durgin JS; Wysocka M; Rook AH
    J Am Acad Dermatol; 2021 Mar; 84(3):597-604. PubMed ID: 33352268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
    Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
    Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.